Bulletin
Investor Alert

Feb. 14, 2020, 1:37 a.m. EST

DiGeorge Syndrome Drug Market Admirable Growth by 2026| Natera, Inc, Roche Sequencing, Enzyvant, Progenity, Inc., Boehringer Ingelheim International GmbH

new
Watchlist Relevance
LEARN MORE

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

or Cancel Already have a watchlist? Log In

Feb 14, 2020 (The Expresswire) -- Global DiGeorge Syndrome Drug Market By Therapy Type (Regenerative Medicine Advanced Therapy and Hormone Replacement Therapy), Treatment Type (Medication and Surgery), Route of Administration (Oral and Injectable), End- Users (Hospitals, Homecare, Specialty Clinics, Others), Geography (North America, South America, Europe, Asia-Pacific, Middle East and Africa) - Industry Trends & Forecast to 2026

Global DiGeorge syndrome drug market is expected to grow at a substantial CAGR in the forecast period of 2019-2026. The growing incidence of DiGeorge syndrome’s population and the development of newer therapies and treatment are the key factors for market growth. Some of the major competitors currently working in the global Digeorge syndrome drug market are Aevi Genomic Medicine, Inc, Bausch Health, Natera, Inc, Roche Sequencing, Enzyvant, Progenity, Inc., Boehringer Ingelheim International GmbH, AbbVie Inc., Amgen Inc, F. Hoffmann-La Roche Ltd, Johnson and Johnson Services, Inc, Angimmune LLC, Sumitomo Dainippon Pharma Co., Ltd., CELGENE CORPORATION, CELLECTAR BIOSCIENCES, INC, eFFECTOR Therapeutics, Inc., IMV Inc, Karyopharm, Neon Therapeutics, Novartis AG and many others.

Get a Sample Report Now @ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-digeorge-syndrome-drug-market

Market Definition:Global DiGeorge Syndrome Drug Market

DiGeorge syndrome is also known as 22q11.2 deletion syndrome or velocardiofacial syndrome is a rare pediatric congenital condition where children are born with absence of chromosome 22. This results to severe immunodeficiency causing poor development of several body systems. Children with DiGeorge syndrome disorders have no ability to fight against infections.

According to the article puplished in Northwestern University, it is estimated that the incident population of DiGeorge Syndrome in the United States around 500 to 750 and over 2.5 million children diagnosed yearly.These growing incidents of DiGeorge syndrome’s population worldwide and robust pipeline for development of newer therapies are the key factors for market growth.

Global DiGeorge syndrome drug market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of Digeorge syndrome drug market for global, Europe, North America, Asia-Pacific, South America and Middle East and Africa.

Market Drivers

  • Vulnerable pediatric population of DiGeorge syndrome

  • Emergence of drugs for treating serious disease such as CNS disorders and cardiovascular diseases associated with DiGeorge syndrome

  • Increase in the rate of RandD initiatives is driving DiGeorge syndrome therapeutics market

Market Restraints

  • Effective treatment is either unavailable or unaffordable

  • Patent expiry from many companies and introduction of generic drugs of branded version is expected to restrain the growth if the market

  • Inadequate knowledge about DiGeorge syndrome in some developing countries

Segmentation:Global DiGeorge Syndrome Drug Market

By Therapy Type

  • Regenerative Medicine Advanced Therapy

  • Hormone Replacement Therapy

By Treatment

  • Medication

  • Surgery

By Route of administration

  • Oral

  • Injectable

By End Users

  • Hospitals

  • Homecare

1 2
This Story has 0 Comments
Be the first to comment

Story Conversation

Commenting FAQs »
Link to MarketWatch's Slice.